Literature DB >> 21795333

Epstein-Barr virus latent membrane protein 1 (LMP1) C-terminal-activating region 3 contributes to LMP1-mediated cellular migration via its interaction with Ubc9.

Gretchen L Bentz1, Christopher B Whitehurst, Joseph S Pagano.   

Abstract

Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1), the principal viral oncoprotein and a member of the tumor necrosis factor receptor superfamily, is a constitutively active membrane signaling protein that regulates multiple signal transduction pathways via its C-terminal-activating region 1 (CTAR1) and CTAR2, and also the less-studied CTAR3. Because protein sumoylation among other posttranslational modifications may regulate many signaling pathways induced by LMP1, we investigated whether during EBV latency LMP1 regulates sumoylation processes that control cellular activation and cellular responses. By immunoprecipitation experiments, we show that LMP1 interacts with Ubc9, the single reported SUMO-conjugating enzyme. Requirements for LMP1-Ubc9 interactions include enzymatically active Ubc9: expression of inactive Ubc9 (Ubc9 C93S) inhibited the LMP1-Ubc9 interaction. LMP1 CTAR3, but not CTAR1 and CTAR2, participated in the LMP1-Ubc9 interaction, and amino acid sequences found in CTAR3, including the JAK-interacting motif, contributed to this interaction. Furthermore, LMP1 expression coincided with increased sumoylation of cellular proteins, and disruption of the Ubc9-LMP1 CTAR3 interaction almost completely abrogated LMP1-induced protein sumoylation, suggesting that this interaction promotes the sumoylation of downstream targets. Additional consequences of the disruption of the LMP1 CTAR3-Ubc9 interaction revealed effects on cellular migration, a hallmark of oncogenesis. Together, these data demonstrate that LMP1 CTAR3 does in fact function in intracellular signaling and leads to biological effects. We propose that LMP1, by interaction with Ubc9, modulates sumoylation processes, which regulate signal transduction pathways that affect phenotypic changes associated with oncogenesis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21795333      PMCID: PMC3196420          DOI: 10.1128/JVI.05035-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  EBNA3C coactivation with EBNA2 requires a SUMO homology domain.

Authors:  Adam Rosendorff; Diego Illanes; Gregory David; Jeffrey Lin; Elliott Kieff; Eric Johannsen
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

Review 2.  Epstein-Barr virus latent membrane protein 1: structure and functions.

Authors:  Hsin-Pai Li; Yu-Sun Chang
Journal:  J Biomed Sci       Date:  2003 Sep-Oct       Impact factor: 8.410

3.  SUMO-1 modification of the C-terminal KVEKVD of Axin is required for JNK activation but has no effect on Wnt signaling.

Authors:  Hong-Liang Rui; Ernest Fan; Hai-Meng Zhou; Zhen Xu; Yi Zhang; Sheng-Cai Lin
Journal:  J Biol Chem       Date:  2002-09-09       Impact factor: 5.157

4.  Ubc9 is a novel modulator of the induction properties of glucocorticoid receptors.

Authors:  Sunil Kaul; John A Blackford; Sehyung Cho; S Stoney Simons
Journal:  J Biol Chem       Date:  2002-01-25       Impact factor: 5.157

5.  Lysine residues of Epstein-Barr virus-encoded nuclear antigen 2 do not confer secondary modifications via ubiquitin or SUMO-like proteins but modulate transcriptional activation.

Authors:  Annette Hille; Akua Badu-Antwi; Daniela Holzer; Friedrich A Grässer
Journal:  J Gen Virol       Date:  2002-05       Impact factor: 3.891

6.  Identification of the structural and functional human homolog of the yeast ubiquitin conjugating enzyme UBC9.

Authors:  T Yasugi; P M Howley
Journal:  Nucleic Acids Res       Date:  1996-06-01       Impact factor: 16.971

7.  Identification of a SUMO-binding motif that recognizes SUMO-modified proteins.

Authors:  Jing Song; Linda K Durrin; Thomas A Wilkinson; Theodore G Krontiris; Yuan Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-23       Impact factor: 11.205

8.  Epstein-Barr virus latent membrane protein 1 activation of NF-kappaB through IRAK1 and TRAF6.

Authors:  Micah Luftig; Efthimios Prinarakis; Teruhito Yasui; Theodore Tsichritzis; Ellen Cahir-McFarland; Jun-Ichiro Inoue; Hiroyasu Nakano; Tak Wah Mak; Wen-Chen Yeh; Xiaoxia Li; Shizuo Akira; Nobutaka Suzuki; Shinobu Suzuki; George Mosialos; Elliott Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-12       Impact factor: 11.205

9.  Latent membrane protein 1 is critical for efficient growth transformation of human B cells by epstein-barr virus.

Authors:  Ulrike Dirmeier; Bernhard Neuhierl; Ellen Kilger; Gilbert Reisbach; Mark L Sandberg; Wolfgang Hammerschmidt
Journal:  Cancer Res       Date:  2003-06-01       Impact factor: 12.701

10.  Epstein-Barr virus latent membrane protein 1 induces synthesis of hypoxia-inducible factor 1 alpha.

Authors:  Naohiro Wakisaka; Satoru Kondo; Tomokazu Yoshizaki; Shigeyuki Murono; Mitsuru Furukawa; Joseph S Pagano
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

View more
  35 in total

1.  Modified Anoikis Assay That Functionally Segregates Epstein-Barr Virus LMP1 Strains into Two Groups.

Authors:  Laura R Wasil; Kathy H Y Shair
Journal:  J Virol       Date:  2018-08-29       Impact factor: 5.103

2.  Assembly of Epstein-Barr Virus Capsid in Promyelocytic Leukemia Nuclear Bodies.

Authors:  Wen-Hung Wang; Chung-Wen Kuo; Li-Kwan Chang; Chen-Chia Hung; Tzu-Hsuan Chang; Shih-Tung Liu
Journal:  J Virol       Date:  2015-06-17       Impact factor: 5.103

3.  Adenovirus regulates sumoylation of Mre11-Rad50-Nbs1 components through a paralog-specific mechanism.

Authors:  Sook-Young Sohn; Patrick Hearing
Journal:  J Virol       Date:  2012-06-27       Impact factor: 5.103

4.  Distinctive Epstein-Barr virus variants associated with benign and malignant pediatric pathologies: LMP1 sequence characterization and linkage with other viral gene polymorphisms.

Authors:  Mario Alejandro Lorenzetti; Magdalena Gantuz; Jaime Altcheh; Elena De Matteo; Paola Andrea Chabay; María Victoria Preciado
Journal:  J Clin Microbiol       Date:  2012-01-11       Impact factor: 5.948

5.  SUMO binding by the Epstein-Barr virus protein kinase BGLF4 is crucial for BGLF4 function.

Authors:  Renfeng Li; Leyao Wang; Gangling Liao; Catherine M Guzzo; Michael J Matunis; Heng Zhu; S Diane Hayward
Journal:  J Virol       Date:  2012-03-07       Impact factor: 5.103

6.  LMP1-Induced Sumoylation Influences the Maintenance of Epstein-Barr Virus Latency through KAP1.

Authors:  Gretchen L Bentz; Charles Randall Moss; Christopher B Whitehurst; Cary A Moody; Joseph S Pagano
Journal:  J Virol       Date:  2015-05-06       Impact factor: 5.103

Review 7.  Epstein-Barr Virus LMP1-Mediated Oncogenicity.

Authors:  Liang Wei Wang; Sizun Jiang; Benjamin E Gewurz
Journal:  J Virol       Date:  2017-10-13       Impact factor: 5.103

8.  KSHV LANA and EBV LMP1 induce the expression of UCH-L1 following viral transformation.

Authors:  Gretchen L Bentz; Anjali Bheda-Malge; Ling Wang; Julia Shackelford; Blossom Damania; Joseph S Pagano
Journal:  Virology       Date:  2013-11-08       Impact factor: 3.616

9.  Epstein-Barr virus latent membrane protein 1 genetic variability in peripheral blood B cells and oropharyngeal fluids.

Authors:  Nicholas Renzette; Mohan Somasundaran; Frank Brewster; James Coderre; Eric R Weiss; Margaret McManus; Thomas Greenough; Barbara Tabak; Manuel Garber; Timothy F Kowalik; Katherine Luzuriaga
Journal:  J Virol       Date:  2014-01-15       Impact factor: 5.103

Review 10.  Viral Carcinogenesis Beyond Malignant Transformation: EBV in the Progression of Human Cancers.

Authors:  Deilson Elgui de Oliveira; Bárbara G Müller-Coan; Joseph S Pagano
Journal:  Trends Microbiol       Date:  2016-04-07       Impact factor: 17.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.